Clinical trials: Hematopoietic Neoplasms
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Hematopoietic/Lymphoid Cancer
Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
Clinical study of CD19 CAR-T in the treatment of blood and lymphatic system tumor has been achieved a breakthrough. The main solution in clinical research is to use CD19 CAR-T infusion alone.
- Trial name
- NCT02903810
- Testing
- Mixed CAR-T Transfer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and…
- Trial name
- NCT06498973
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Myeloid Malignancies
Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies
The goal of this single-arm phase II study is to test in patients with non-remission myeloid malignancies undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT05807659
- Testing
- fractionated busulfan-based conditioning regimen
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sichuan University
Measurable Residual Disease
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at high risk of relapse
- Trial name
- NCT06000306
- Testing
- Digital Droplet PCR
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Zhejiang University
Leukemia, Lymphoma
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection.
- Conditions
- Leukemia, Lymphoma, HIV
- Trial name
- NCT01410344
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
Evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1).
- Trial name
- CBF(+)AML (NCT01146977)
- Testing
- HDAC chemotherapy, Autologous HCT
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Cooperative Study Group A for Hematology
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system.
- Conditions
- Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse, High Risk Acute Lymphoblastic Leukemia
- Trial name
- NCT05066958
- Testing
- boost anti-viral immunity after T-cell depleted HSCT
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Blood Cancer, Lymphoma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function.
- Conditions
- Blood Cancer, Lymphoma, Leukemia, Myeloma
- Trial name
- NCT07052916
- Testing
- Music Therapy/MT, Therapist-Attention Music Education/TAME Control
- Where
- 7 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous…
- Trial name
- NCT02724904
- Testing
- Allogeneic stem cell transplantation, Fludarabine, Thiotepa
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine with or without rituximab in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma or…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00068315
- Testing
- bortezomib, fludarabine phosphate, rituximab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and children with relapsed NBL have an overall 3 year survival rate of < 10%.
- Trial name
- NCT00874315
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 4 sites in United States
- Sponsor
- Nationwide Children's Hospital
Acute Myeloid Leukemia
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Elderly patients with acute myeloid leukemia (AML) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders.
- Trial name
- NCT06571825
- Testing
- Venetoclax, Allogeneic transplant
- Where
- China
- Volunteers
- 118 people
- Sponsor
- He Huang
Multiple Myeloma, Minimal Residual Disease
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after…
- Trial name
- NCT06463717
- Testing
- Transplant, Autologous, Chemotherapy drug
- Where
- China
- Volunteers
- 210 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hematologic Malignancies
Safety of Romiplostim (Nplate®) Following UCBT
This is a single institution, phase I dose escalation study of weekly romiplostim post umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by day +30.
- Trial name
- NCT02046291
- Testing
- Romiplostim
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Graft -Versus-host-disease
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.
- Trial name
- ABRAXAS (NCT07808112)
- Testing
- Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Medical College of Wisconsin
Sickle Cell Disease, Thalassemia, Beta
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow.
- Conditions
- Sickle Cell Disease, Thalassemia, Beta, Thalassemia
- Trial name
- NCT05736419
- Testing
- Fludarabine, Cyclophosphamide, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
AML, ALL
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood…
- Conditions
- AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01012492
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Boston Children's Hospital
Hematologic Malignancy, Hematopoietic/Lymphoid Cancer
Positive Psychology Intervention In HSCT
The main purpose of this research study is to determine if a positive psychology-based program in people who have received a stem cell transplant for blood cancer treatment is feasible and acceptable, and can help improve…
- Conditions
- Hematologic Malignancy, Hematopoietic/Lymphoid Cancer, Blood Cancer
- Trial name
- PATH-3 (NCT05147311)
- Testing
- Positive Psychology Intervention
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Brigham and Women's Hospital
Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
This phase I trial studies the side effects and the best dose of donor lymphocyte infusion when given together with reduced intensity conditioning regimen before partially matched donor stem cell transplant in treating patients…
- Conditions
- Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IIB Mycosis Fungoides and Sezary Syndrome, Stage IIIA Mycosis Fungoides and Sezary Syndrome
- Trial name
- NCT02548468
- Testing
- Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.